Development and differentiation of the eutherian zygote to a laminar blastocyst occur during the journey through the reproductive tract. In the absence of anatomical union, synchronization of embryonic and maternal physiologies must rely on diffusible signals to support and optimize developmental potential throughout this period of about 6 days.
Discoveries of the activities of growth factors and their receptors in general biology during the late 1970s coincided with a recognition that they may be the means by which preimplantation embryos optimize their potential. Concurrently, application of the assisted reproductive techniques developed for animals to human infertility had achieved success with the birth of Louise Brown (Steptoe and Edwards, 1978) . This event invigorated interest in embryo culture and, in particular, the roles of growth factors which were known to play regulatory roles in development in better understood non-mammalian developmental models such as amphibians, sea urchins and chickens (for comprehensive reviews see Schultz and Heyner, 1993; Kaye and Harvey, 1995; Pampfer and De Hertogh, 1996) .
Circuits
The classic definition of endocrine activity ('a hormone is secreted from a gland and carried by the circulation to target tissues') has broadened to include circuits that are local (paracrine, a refinement of which is juxtacrine, where secreting and receiving cells adjoin) or within the one cell (autocrine). Thus, in considering the roles of growth factors in preimplantation development, we are concerned with molecules originating in the embryo (for example, insulin-like growth factors, IGF), the reproductive tract (for example, tumour necrosis factor α, TNF-α) or distant endocrine glands (insulin). Targets for these molecules could be the secreting cells themselves or non-secreting target cells in the embryo or reproductive tract (Fig. 1a) .
Insulin, insulin-like growth factors and their receptors
These three related proteins and their receptors have been widely studied in preimplantation embryo development. Insulin, a 6 kDa endocrine protein secreted by the pancreatic islets of Langerhans, classically regulates whole body glucose metabolism by anabolic actions in liver, adipose and muscle tissue. However, it also promotes growth of cells in culture. IGF-I and IGF-II are similar to proinsulin, but differ from insulin in that they are secreted by many cells and travel in extracellular fluids bound to a family of IGF-binding proteins (IGFBP). Structural similarities between the insulin receptor and type 1 IGF receptor enable both to bind insulin and IGF-I, although the affinity for the homologous ligand is about 100 times greater than for the crossreacting ligand. IGF-II binds with highest affinity to the type 2 receptor (Table 1) which is structurally unrelated to either the insulin or type 1 receptor and also carries a separate binding site for mannose 6 phosphate (M6P). The prevailing view is that the primary function of this dual receptor protein is associated with the M6P receptor. As IGF-II also binds to the type 1 receptor with affinity approaching that of IGF-I (Table 1) , growth factor actions of IGF-II are considered to be primarily through this crossreaction. Nonetheless, there are examples in general, as well as in preimplantation biology, that point to regulatory functions of IGF-II mediated by the type 2/M6P receptor (Sara and Hall, 1990) .
Insulin
The first evidence for participation of a specific growth factor in blastocyst physiology was obtained through the amplification available from metabolic incorporation of [ 14 C]glucose (Wales et al., 1985) . Similarly, studies using incorporation of amino acids into protein demonstrated that the insulin response arose during compaction (Harvey and Kaye, 1988 ) and persisted in both trophectoderm and inner cell mass lineages of the blastocyst (Harvey and Kaye, 1991a) . Dose-response studies
The robust independence of preimplantation embryo development in vitro suggests that the developmental programme is autonomous. The rapid accumulation of evidence during the last decade for participation of many hormones, growth factors and their receptors in these early stages of embryogenesis has challenged this conclusion. In this review, the insulin and epidermal growth factor families, which have been best studied in mice, are used to illustrate the different roles growth factors may play in preimplantation physiology and the circuits that possibly mediate their participation. Tumour necrosis factor α, an inhibitory factor and growth hormone previously considered to be restricted to orchestrating postnatal growth and development, is also discussed. In the absence of results indicating the existence of a master regulatory factor, the data support the hypothesis that the redundancy of growth factor actions may provide fail-safe protection to the preimplantation developmental programme.
provided evidence that the insulin receptor mediated the stimulatory actions of insulin. However, insulin did not stimulate cell proliferation in trophectoderm, as it did in the inner cell mass (Harvey and Kaye, 1990a) . In contrast, protein synthesis in both tissues was increased (Harvey and Kaye, 1990a, 1991a) . The resistance of trophectoderm proliferation to insulin suggests that the receptors in these cells are coupled to a different set of signalling pathways from those in the inner cell mass. Moreover, acceleration of cell proliferation in whole blastocysts by insulin was entirely restricted to the inner cell mass, which is isolated from exogenous proteins by the tight junctions of the trophectoderm. Thus insulin must cross the trophectoderm to the inner cell mass by transcytosis, indicating another difference between the two lineages in the way they handle insulin receptors.
Visual images of insulin binding to morulae and blastocysts (Rosenblum et al., 1986) and of specific insulin receptor antibody staining (Harvey and Kaye, 1990b) confirmed the conclusions of the metabolic studies about the ontogeny of insulin receptor expression. Ultrastructural analysis revealed the transtrophectodermal passage of exogenous insulin, its binding to receptors on the apical trophectoderm, its gathering in clathrincoated pits and, in the course of transcytosis through the trophectoderm, to the inner cell mass cells, where it was again endocytosed in clathrin-coated pits (Heyner et al., 1989) . Insulin receptors appeared to be distributed uniformly over the cell membranes of the blastocyst.
Insulin-like growth factor
Meanwhile, endocrinologists had attributed many of the growth-promoting effects of insulin to its crossreaction with the type 1 IGF receptor. In mouse blastocysts, competitive radioligand binding studies indicated expression of both insulin and IGF receptors (Mattson et al., 1988) . Type 2 IGF/M6P receptors were first expressed in two-cell mouse embryos, persisting through cleavage and blastocyst formation to both inner cell mass and trophectoderm (Harvey and Kaye, 1991b) . The appearance of the type 1 receptor has not been observed before the morula stage, but it also persisted in both tissues of the blastocyst. Apical and basolateral membranes of trophectoderm cells and the inner cell mass membranes seemed to express both insulin and type 1 receptors uniformly (Fig. 1) . After ligand binding, the apical trophectodermal type 1 receptor and the insulin receptor appeared to follow similar endocytic pathways in the blastocyst (Smith et al., 1993) . 
TGF-α

RNA phenotyping
The family's receptors were clearly products of the embryonic genome, since mouse embryos do not begin transcription until the two-cell stage. Reverse transcription of RNA coupled to the polymerase chain reaction (RT-PCR) confirmed these conclusions by demonstrating mRNA encoding insulin receptor, and both IGF receptors. mRNA encoding IGF-II was first expressed in two-cell embryos and persisted to later stages (Rappolee et al., 1992) . Although transcripts for IGF-I or insulin were not detected in this study, mRNA encoding IGF-I was later found in unfertilized eggs and preimplantation embryos at all stages (Doherty et al., 1994) . The conflict between these two results has not been adequately addressed and leaves a reservation about the reliability of negative RT-PCR results.
Simultaneous expression of both IGF and the type 2/M6P receptor from the two-cell stage, supplemented from compaction, by the type 1 and insulin receptors, provided the potential for autonomous embryonic regulation as well as embryo-maternal communication through autocrine or paracrine circuits from the earliest stages of embryonic activation. However, the presence of maternal insulin in uterine fluids (Heyner et al., 1989) , but absence of any evidence for embryonic insulin, confirms this hormone as a long range maternal conduit for co-ordination of embryonic and maternal physiologies.
Comparative studies of expression
Comparison of the transcription of the insulin family in preimplantation embryos of other species shows the mouse to be atypical. It fails to express IGF-II in oocytes; in addition, the insulin and type 1 receptors are not expressed until compaction. In other species, these are all provided in the oocyte and persist in preimplantation development through embryonic transcription (Table 2 ). The failure to observe the type 2/M6P receptor in sheep most likely arises from a technical fault, as the M6P receptor function is critical in targeting proteins to lysosomes which are important in blastocyst activity. This provides further support for the hypothesis above that maternal insulin is involved in endocrine regulation of preimplantation embryonic physiology. Studies in diabetic rodents provide support for the operation of this endocrine circuit in vivo (Beebe and Kaye, 1991; De Hertog et al., 1992) .
Preimplantation circuitry
Use of antisera and antisense oligodeoxynucleotides (ODN) to attenuate activity of specific ligands and receptors has provided some insight into the operation of autocrine or paracrine IGF circuits. Antisense ODN for IGF-II reduced the rate of development of mouse blastocysts from two-cell embryos and the number of cells in the resultant blastocysts, leading to the conclusion that an autonomous IGF-II type 1 IGF receptor circuit modulates preimplantation embryonic physiology in vitro (Fig. 1b) (Rappolee et al., 1992) . Before accepting this conclusion, the high potency of IGF-II in stimulating protein synthesis, blastocyst formation and cell proliferation (10-100 pmol l -1 ; Harvey and Kaye, 1992a) must be considered to indicate that embryonic IGF-II may also form an endogenous circuit with the type 2/M6P receptor.
Biological significance of insulin-like growth factor effects
The diverse physiological parameters that are regulated by this family are presented in Table 3 and their potencies are given in Table 1 . The stimulation of cell proliferation by high concentrations of insulin during cleavage (Gardner and Kaye, 1991) and of compaction by both IGF-I and IGF-II (Harvey and Kaye, 1992a,b) suggest that the type 2/M6P receptor may mediate these actions, since it is the only family receptor expressed at this early stage of development. The proposal that, as insulin and IGF selectively increase the number of cells in the inner cell mass, they may direct differentiation of cells in the compacted morula into this population and away from trophectoderm lineages has not been assessed. In summary, this family appears to be associated with effects on cell proliferation in cleaving embryos and blastocysts and differentiated actions in blastocysts.
Although the high potencies of insulin and IGF on embryos (Table 1) point to a real reproductive significance, apart from the diabetic studies referred to above, few experiments have assessed the role of these signalling systems in vivo. Unfortunately, the diabetic model is complicated by the multifactorial disturbances such as hyperglycaemia and ketosis caused by acute removal of maternal insulin. In an alternative approach, treatment of mouse embryos with insulin during preimplantation culture increased formation and number of cells of blastocysts, whose fetal growth rate after transfer was also increased by about 5% (Kaye et al., 1992) . A similar but non-significant increase was reported from a smaller study in rats (Zhang and Armstrong, 1990) . Thus, the more rapidly developing blastocysts with more cells produced by the insulin treatment in vitro appear to have had a greater fetal growth rate than their controls after transfer. This conclusion is supported by the observation that transgenic mice with their type 1 receptor or either IGF gene deleted by homologous recombination produce smaller or non-viable pups (DeChiara et al., 1990; Baker et al., 1993) .
Epidermal growth factor, transforming growth factor α and the epidermal growth factor receptor
This family has been particularly associated with the physiology of the trophectoderm, blastocyst expansion and implantation in mice, in which epidermal growth factor (EGF), like insulin, is not produced by embryos and must be produced by the mother. Transforming growth factor α (TGF-α), like IGF, is an embryonic product and so may constitute an endogenous embryonic regulator. Epidermal growth factor and TGF-α have significant sequence homology and bind with equal affinities to the EGF receptor. TGF-α is secreted by many transformed cells but may also be bound to a transmembrane protein from which it is released by proteolytic cleavage. An analogous situation occurs with EGF, which may occur as heparan-binding EGF-like growth factor (HBEGF), which is also a ligand for the EGF receptor. Therefore, these ligands may be restricted to juxtacrine circuits while protein bound and after release participate in paracrine circuits. The roles of the family in preimplantation development have been reviewed extensively (for example, Wiley et al., 1995) so comparisons with the insulin family will be highlighted.
Circuits and actions
Epidermal growth factor receptors were found mostly in components of the trophectodermal transcytosis pathway, on the basolateral membranes of trophectoderm cells and on inner cell mass cells (Dardik et al., 1992) . This contrasts with the insulin and type 1 IGF receptors which were uniformly distributed in the blastocyst membranes. Epidermal growth factor in freshly flushed embryos probably originated in the endometrial gland cells, since none was found in embryos that had been cultured in EGF-free medium. In contrast, embryonic TGF-α was found almost exclusively in the inner cell mass cells. 124 Peter L. Kaye Blastocysts treated with EGF increased rates of expansion and trophectoderm protein synthesis (Dardik and Schultz, 1991) . Anti-EGF receptor antibodies mimic the effects of EGF/TGF-α, (as for insulin receptor antibodies), but antisense ODN for EGF receptor or TGF-α attenuated blastocyst formation and cell proliferation (Brice et al., 1993) . Taken together, these observations suggest that TGF-α derived from inner cell mass acts on basolaterally arrayed EGF receptors in a paracrine circuit to influence trophectoderm functions such as blastocyst formation and expansion. In support of this conclusion, TGF-α caused increased expression of mRNA coding for proteins participating in embryonic power generation (Babalola and Schultz, 1995) . These observations suggest that TGF-α may affect cavitation and blastocyst formation by regulating the generation of the trans-trophectodermal ion currents that drive these processes. Parallel studies with the insulin family have not been reported. Actions of the TGF-α/EGF family are also important at implantation during blastocyst attachment and trophoblast invasion. Epidermal growth factor receptor may aid in blastocystendometrium attachment, since downregulation of EGF receptor in trophectoderm delays implantation (Paria et al., 1993) . A candidate endometrial ligand for attachment to trophectodermal EGF receptor is HBEGF which is induced by proximity of the blastocyst (Das et al., 1994) and to which blastocysts bind when expressed by cells in vitro (Raab et al., 1996) . In contrast, delayed implanting blastocysts lacking EGF receptor are much less adherent to cells expressing HBEGF. Further support for EGF mediation of blastocyst endometrial binding comes from observations that blastocysts express mRNA encoding fulllength receptor while the uterine mRNA encodes only a truncated EGF receptor (Tong et al., 1996) . Maternal EGF may also stimulate expression of extracellular matrix proteinases by trophectoderm outgrowths (for discussion, see Harvey and Kaye, 1995) . The regression of the inner cell mass and failure to implant in mice with EGF receptor gene deletion supports the overall conclusions (Sibilia and Wagner, 1995; Threadgill et al., 1995) .
Comparison of the insulin and EGF families
Although analyses of the roles of the two families have followed divergent paths, many actions are common, such as stimulation of trophectoderm activity and blastocyst formation. Nonetheless, a generalization compatible with wider views of the functions of these families is that the insulin family, because of uniform receptor expression, is broadly concerned with both cell proliferation and gross differentiation. The more specific effects of the EGF family suggest its key role is in trophectoderm differentiation in the morula and blastocyst (Wiley et al., 1995) . As mentioned above, insulin and IGF may be associated more with inner cell mass function, because of their selective stimulation of inner cell mass proliferation which appears to lead to increased fetal growth. Results from studies of the effects that ligands of each family have on aspects of the recovery of irradiated mouse embryos support this conclusion (Peters et al., 1996) , as does comparison of the primary outcomes of selected null mutation in mice, in which the IGF deletions impact on growth and those of the EGF family impact on inner cell mass development and implantation. A significant difference between the families is the exclusive maternal source of insulin in all species studied. It is difficult to reconcile the embryotrophic effects of insulin with its classic endocrine regulation of energy flux. However, absence from embryos of the key insulin target, glucose transporter 4, which rapidly delivers large amounts of post-prandial blood glucose to muscle and fat for anabolism, indicates that insulin is acting during development as a growth factor. Moreover, the interaction of IGF with IGFBP which may be secreted by embryos (Hahnel and Schultz, 1994) suggests that insulin has some separate role from IGF, the most important circuits of which may be autocrine and paracrine. Finally, the close regulation of maternal IGF and EGF activity by sex steroids suggest that these paracrine circuits are maternally controlled.
Tumour necrosis factor α and growth hormone
Tumour necrosis factor α presents the best evidence of an inhibitory influence on preimplantation development. Growth hormone (GH) has traditionally been considered a master determinant of postnatal growth, but now may participate in a hierarchical circuit, regulating IGF participation in the first events of embryonic development.
Tumour necrosis factor α
Although initially described as a toxin secreted by macrophages, there is much evidence that TNF-α plays a crucial role in early pregnancy. The protein and its mRNA have been detected in oocytes, oviductal epithelium, uterine endometrium and endometrial glands of several species. Studies of cycling endometria revealed a close parallel between TNF-α expression and cell proliferation and hypertrophy, suggesting that TNF-α activity is governed by the maternal sex steroid profile (Hunt, 1993) . However, complete ablation of either of the two forms (p60/80) of TNF-α receptor in mice by transgenic manipulation has no apparent effect on fertility (Beutler and Van Huffel, 1994) .
In contrast to the previously discussed factors that have all been stimulatory, TNF-α inhibited cell proliferation and blastocyst formation in vitro mediated by the p60 TNF-α receptor (Pampfer et al., 1994) . Antisense ODN reduced embryonic expression of mRNA encoding this receptor by about 80% and attenuated the sensitivity of rat blastocysts to exogenous TNF-α (Pampfer et al., 1995) . As attempts to show TNF-α expression in preimplantation embryos have been unsuccessful, maternal TNF-α acting in a paracrine route is proposed to inhibit cell proliferation in preimplantation embryos in vivo. The close correlation between endometrial TNF-α expression and sex steroid profiles provides a link through which maternal and embryonic physiologies could be co-ordinated. The balance between the stimulatory activities of the IGF and EGF and inhibition by TNF-α may provide a sensitive control on key aspects of preimplantation development such as number of cells and blastocyst formation.
Growth hormone
Growth hormone is a 22 kDa peptide hormone whose secretion into the circulation by anterior pituitary somatotropes is controlled by the hypothalamus. The GH receptor is a member of the superfamily of cytokine receptors. Many organs express GH receptor, but most notable is the liver, which increases IGF-I secretion in response to GH and regulates growth in many tissues including long bones. Despite its presence at high concentration in human and rodent fetuses, GH has been excluded from a role in embryonic growth. However, in humans, newborn Laron dwarfs who lack functional GH receptors are more than two standard deviations shorter than average, suggesting that embryonic response to GH is required to optimize fetal growth (Laron et al., 1972) . Furthermore, recent results show that GH and its receptor play a role in preimplantation physiology.
Since both insulin and IGF-I have been detected in the uterus, maternal GH may also penetrate to this region and activate putative preimplantation GH receptors. mRNA encoding GH receptor and protein were found in embryonic stem cells which may not faithfully represent their preimplantation precursor cells. In any case, preliminary studies showed expression of mRNA encoding GH receptor in blastocysts, although protein expression was not investigated (Ohlsson et al., 1993) . Growth hormone increased blastocyst formation and hatching with a bell shaped response curve typical of the GH receptor dimer with maximum effect at 200 ng GH ml -1 (Drakakis et al., 1995) .
A detailed study of the preimplantation embryonic GH-GH receptor circuit confirmed that the receptor and the mRNA encoding it are expressed in preimplantation mouse embryos (Pantaleon et al., in press ). The mRNA encoding the GH receptor was present in fertilized oocytes and subsequently followed the pattern typical of maternal mRNA which is replaced by embryonic transcripts. The intense oocyte signal decreased at the two-cell stage (when the protein was first observed) and increased as development proceeded. Stimulation of glucose transport and protein synthesis by GH followed the bell-shaped dose-response curve described above, but with the much higher potency of <1 ng GH ml -1 . If a source of GH that acts on the embryo could be found, these results would link embryonic IGF-I with its classic regulator, GH. Embryonic expression of GH was observed in blastocysts and the encoding mRNA was detectable, coincident with the type 1 IGF receptor from the morula stage. The compacted preimplantation embryo therefore contains an endogenous GH-GH receptor circuit in addition to an IGF-I type 1 receptor circuit. Furthermore, GH may modulate preimplantation growth and development through stimulation of IGF-I secretion. If the upregulation of GH receptors by retinoic acid that occurs in embryonic stem cells (Ohlsson et al., 1993) also applies in the blastocyst, a trilaminar retinoic acid-GH-IGF-I hierarchical pathway may operate with retinoic acid participating in regulation of preimplantation physiology.
Conclusion
When Louise Brown was born twenty years ago, participation of growth factors in preimplantation physiology was unknown. Current knowledge shows this to be a complex area with some common threads (such as the similar actions of many growth factors) but many unanswered questions. Does the early undifferentiated embryo express the full panoply of growth factor circuits? Do they become downregulated as differentiation progresses? Many factors (for example, EGF, IGF, TNF-α) clearly form paracrine circuits between the supporting maternal reproductive tract and the embryo, while others (IGF, TGF-α, GH) appear also to form autonomous regulatory embryonic circuits. To date only TNF-α provides an inhibitory balance to the stimulatory actions of other growth factors. Is there some hierarchical control system, perhaps involving retinoic acid? Each of these local regulatory systems seems to be orchestrated by the maternal sex steroid profile, suggesting that preimplantation development is modulated maternally. Yet insulin can also be classified as a maternal endocrine growth factor directly regulating preimplantation embryonic physiology.
Technological advances have moved research beyond discovery and definition of pathways into post-receptor mechanisms, but a clear understanding of the function of overlapping growth factor actions still eludes us. The most plausible conclusion is that the redundancy of growth factor actions provides fail-safe protection to the preimplantation developmental programme, protecting it from trauma and stress during the phase of anatomical independence. Despite the impetus given by the burgeoning application of assisted reproductive techniques to human reproductive medicine, this new knowledge and its demonstrated benefit to development in vitro have, aside from rare reports (for example, O'Neill et al., 1989) , failed to produce increases in the success of in vitro fertilization technology. 
